MXPA98009256A - Antimicrobial treatment for herpes simplex virus and other infectious diseases - Google Patents

Abstract

An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.

Description

ANTIMICROBIAL TREATMENT FOR SIMPLE HERPES VIRUSES AND OTHER INFECTIOUS DISEASES BACKGROUND OF THE INVENTION The present invention relates to the herpes virus and, more particularly, to medical treatments for the herpes virus and other microbial infestations. The herpes simplex virus (HSV), commonly known as the "herpes virus" or "herpes", is an infectious disease which has reached crisis proportions nationally, with estimated numbers of infected people from 70 to 80% of our population , as reported by the American Social Health Association (ASHA) and grows annually by 500,000 people or more. There are two common types of herpes, herpes simplex virus 1 (HSV 1) and herpes simplex virus 2 (HSV 2). Herpes enters the human body through tiny breaks in the epidermal tissue, usually by contact with an infected host, and is marked by the eruption of one or more vesicles, usually in groups, followed by an incubation period of approximately four. to ten days. Typically, the course of the infectious eruption begins with the prodrug stage; progresses to the vesicular eruption; followed by: ulceration; coalescence; resolution; and latency period. The rash may last for several weeks and on average the last three weeks. In some individuals with immune compromise, the rash may last for months. The vesicles can appear anywhere on the skin or mucosa, typically appearing on the lips as cold inflammations, glands, oral mucosa, conjunctiva and cornea, genitals, anal mucosa and peri-anal tissue. The symptoms of herpes include; inguinal swelling, pain, fever, malaise, headaches, muscle aches and swollen glands. Some individuals with the trigeminal nerve affected by oral herpes, have acute facial pains, difficulty swallowing, eating and facial swelling. Individuals with the affected sacral nerve have severe pain in the upper leg, swelling and great difficulty walking. The infection of herpes simplex virus (HSV) is recrudescent, resides in the nervous ganglia, then it is recurrent due to, as is still unknown, some stimuli. Recurrent herpetic infections can be precipitated by almost anything, including: prolonged exposure to sunlight; deficiencies of nutrition, stress, menstruation; immunosuppression; certain foods; drugs; febrile diseases; etc. Recently, the herpes virus was isolated from the heart tissue.

HSV 1 and HSV 2 infections have several serious health threats, which often cause: blindness, increased risk of cervical cancer; aseptic meningitis and encephalitis; neonatal deaths; viremia; etc. The devastating effects of this disease go far beyond the medical reach of human suffering; HSV is responsible for serious psychological and emotional distress, as well as substantial economic losses to the nation and the world. Several treatments for herpes have been proposed, which have included the topical application of such agents as povodone-iodine, iodoxuridine, trifluorothymidine or Acyclovir. Such treatments have had varying degrees of success. Most of the previous treatments have proven to be disappointing. Acyclovir, taken orally for the systemic treatment of HSV, is somewhat effective. However, Acyclovir is only successful in interrupting the replication of the virus and is useful in systemically treating infectious rashes. Nothing so far has proven to be really effective topically. Acyclovir resistant strains have been reported. With individuals with the Syndrome of Auto-Immuno-Deficiency (AIDS) they are seriously compromised in immunological form and suffer especially debilitating rashes of the HSV. Additionally, individuals with AIDS can carry strains resistant to Acyclovir HSV, which can make Acyclovir ineffective in these individuals. Therefore, it is very important to develop a safe and successful medical treatment to overcome these very serious herpes virus problems.

SUMMARY OF THE INVENTION Medical treatment and improved medicines are provided which, when applied in a topical manner, rapidly relieve pain and heal lesions of the herpes virus. Advantageously, medical treatment and improved medicines are safe, cheap and effective. This improved medicine, also referred to as Viracea, comprises a novel medical composition, formulation, antimicrobial compound and solution. The new medical antimicrobial treatment and microbicide medicine are successful in treating primarily the herpes simplex virus (HSV 1 and HSV 2) topically and may be useful in treating other herpes-related microbial infections, including, but not limited to: varicella zoster virus (herpes zoster) and cytomegalovirus. In some circumstances, it may be useful to use the novel medicine systemically. Advantageously, the medical treatment and improved medicines of the present invention surprisingly provided good, unexpected results. The initial topical test, in vivo, showed pain relief in minutes and total accelerated resolution of the vesicular eruption in all tested individuals. When the medical treatment and medicines of the invention are delivered in the prodrome phase, the infection is interrupted and no further eruptions occur. The in vitro test of the novel medical treatment and medicines, showed very surprisingly inhibitory effects in the herpes virus. Conveniently, the novel medicine is obtained from substances or chemical products, not registered (OTC), readily available and provides a safe, comfortable, economical and user-friendly treatment. While novel compounds of medicine and antimicrobial compounds are particularly useful in drastically inhibiting the herpes simplex virus, it may be useful in treating other diseases (microbes) that cause diseases), such as: human immunodeficiency virus (HIV) infection, Epstein-Barr virus, papilloma virus, cellulitis, staphylococcus, streptococcus, mycobacteria, influenza, parainfluenza, adenovirus, encephalitis, meningitis, arbovirus, arenavirus, anaerobic bacillus, picornavirus, coronavirus and sinsitialvirus, as well as varicella viruses zoster and cytomegalovirus.

This ease of use of the microbicidal solution provides a moderately water-resistant coating, when applied to any prodromal tissue or the erythematous lesion of vesicular herpes. In the contact, there is a slight itching effect. Within minutes of the application, the pain of the infection is reduced. Gradually, inguinal swelling, fever, discomfort, body aches and nervous involvement subside. Typically, within twenty-one hours, all external symptoms and physical manifestations of the infection resolve and the vesicle dries up and resolves. A beneficial effect, particularly surprising, provided by this medicine of the invention, is that, when applied to a first sign of eruption, the prodromal stage, all the symptoms and signs of subsequent infectious eruptions and stop! No eruptions or any further scale of infection symptoms appear. Literally they stop! the eruptions. Conveniently, the novel medicine (medical composition) includes inhibitors of microbes, which inhibit, suppress and stop the misrobic infections of the microbes that cause diseases. The microbial inhibitors comprise antimicrobial isolates, botanical extracts or phytochemicals, from at least a portion of one or more of the special plants listed below. The microbial inhibitors may comprise viral inhibitors, to inhibit viral diseases, such as: herpes simplex virus 1 (HSV 1), herpes virus 2 (HSV 2), varicella zoster virus (herpes zoster), cytomegalovirus HIV , Epstein-Barr virus, papilloma virus, viral influenza, parainfluenza, adenovirus, viral encephalitis, viral meningitis, arbovirus, arenavirus, picornavirus, coronavirus and sinsitialvirus. The microbial inhibitors may also comprise bacterial inhibitors to inhibit beetle diseases, such as: cellulitis, staphylococci, streptococci, mycobacteria, bacterial encephalitis, bacterial meningitis and anaerobic bacilli. In some circumstances, the microbial inhibitors may include fungal inhibitors. Better results are obtained if Echinacea or other flats are not used in medicine in their raw, untreated and uncut state. For even better results, the medicine may exclude: Arabinose, betaine, cellulose, copper, fructose, fatty acids, galactose, glucose, iron, potassium, proteins, resins, sucrose, sulfur, vitamin A, vitamin C, vitamin E and xylose . The improved medical treatment provides a novel method and process to be used in the treatment of previous infectious diseases, by applying microbial inhibitors on the microbially infected area and by keeping these microbial inhibitors in the infected area (region or surface), until the symptoms external and the physical manifestations of the infection disappear, reside or resolve around the infected area. The medicine can be applied by spraying, smearing, sprinkling, cleaning, sponging, brushing, emptying, distributing, covering or densely coating the medicine on the areas infected by microbes, such as: oral mucosa, nasal mucosa, vaginal tissue, tissue labial, anal tissue, peri-anal tissue, lips, cutaneous tissue, subcutaneous tissue, eye tissue, conjunctiva and eyelids. While medical treatment and medicine are particularly useful for inhibiting herpes and other infectious diseases in humans (humans) (homo sapiens), they may also be useful for veterinary purposes to treat viral infections and of infectious bacteria and diseases in animals, such like dogs, cats, birds, horses, cows, sheep, pigs and other ranch animals, like rodents and other animals seen in zoos. Preferably, the improved medicine, medical composition or microbial compound is a phytochemical concentrate, which is combined and applied, concurrently or concurrently, with a surfactant and a carrier, solvent or diluent, to deliver a medicinal microbicidal solution. For this purpose, the microbicidal solution of interest comprises an antimicrobial detergent surfactant with botanical extracts. The surfactants are preferably cationic surfactants, which may comprise a single or any number of quaternary ammonium chlorides, having 6 to 18 carbon atoms, such as alkylbenzyldimethylammonium chloride, mixtures of alkyl-benzyldimethiamonium chloride, alkyldimethyl sulphide / ethylbenzyl-onium, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxy-phenoxyethyldimethylbenzylammonium chloride, N- (C ^ C ^ Cigidimethylbenzylammonium chloride, benzalkonium chloride, octyldecyldimethylammonium chloride, didecyl-di-ethylammonium chloride, dioctyldimethylammonium chloride, dialkyldimethylammonium chloride, dialkylmethylbenzylammonium chloride, octyldecyldimethylammonium chloride, di-ethylbenzylammonium chloride, lauryldimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, didecyldi ethylammonium chloride, dioctyl dimethyl ammonium chloride, alkyl chloride bensylammonium and preferably the alkylbenzyldimethylammonium chloride, more preferably benzalkonium chloride. The activity range of the cationic surfactant can be from 5 to 90%, but, for best results, it is from 8 to 20%. Quaternary ammonium salts are readily available commercially. In some circumstances, it may be useful to use other surfactants, such as, but not limited to: DMSO, glycrylic acid, surfactants, enzyme surfactants, ampholytic surfactants, ambiguous surfactants and nonionic surfactants. The surfactants may comprise detergents, re-irrigating agents, emulsifiers, defoamers and / or additives that reduce surface tension. The carriers are useful for mixing the constituents, maintaining the constituents in solution and providing an easy method of application to the affected area, either by spraying, dripping or applying. While an aqueous solution, preferably a sterile aqueous carrier and a solvent, are preferred for the best results, in some circumstances it may be convenient to use another liquid or solid carrier, such as glycerin, mineral oil, silica, cottonseed oil, coconut oil, vegetable oil, seed dressing, fish oil or animal oil, alcohol, talcum powder, corn flour, beeswax, carnauba wax, beta-carotene, gall oil, camphor oil, soluble vitamins, minerals soluble, rapeseed oil, walnut oils, olive oil, liposomes, ascorbic acid, ass herb oil, pycnogenol, grape seed oil, lanolin, Ethocyn, collagen, aloe vera, bee pollen, royal jelly , chondroitin sulfate A, sea vegetables, EDTA, fatty acids, herbs, lecithin, bioflavinoids, grain oils or powders, algae, teas, vinegars, acidophilus, cell salts, ascorbic acids, hydra 5, glandul ares, amino acids, psyllium, plant derivatives or other sterile carriers. The antimicrobial isolates of botanical or phytochemical extracts, contained in this new medicine and medical treatment, may include: Arabinose, betaine, copper, echinacea, equinacin B, echinacoside, equinolone, enzymes, fructose, fatty acids, galactose, glucose, acid glucuronic, inulin, inuloid, iron, pentadecadiene, polyacelylene compounds, polysaccharides, such as, but not limited to, arabinogalactan, potassium, protein, resin, rhamnose, sucrose, sulfur, tannins, vitamins A, C and e, xylose .. For best results, phytochemical concentrates include the above phytochemicals, which exclude Arabinose, betaine, cellulose, copper, frustose, fatty acids, galactose, glycoside, iron, potassium, protein, resin, sucrose, sulfur, xylose and vitamins A, C and E.

The botanical, isolated antimicrobial and phytochemical extracts are separated, extracted and isolated from plant parts, such as: pimpinella anisum, myroxylon, arctostaphylus, carum, capsicum, eugenia mytacea, coriandrum, inula, allium, gentiana, juniperus, calendula, oríganum, mentha labiate, commiphora, plantago, rosmarinus, ruta, baptisa, artemisa, sage, mentha, parthenium integrifolium, eualyptus, asteriacea, and preferably of the genus of Kchinacea of the family Astericaea, that is, Echinacea purpurea, Echinacea angustofolium, Echinacea pallidae, Echinacea vegatalis, Echinacea atribactilus and its cultivated varieties. For best results, the phytochemicals and antimicrobial isolates are extracts of Echinacea purpurea and Echinacea angustí fol ium. The technology of the invention, treatment and medicine provide very attractive, unexpected, surprisingly good and consistent results. Tests show that the microbicidal solution (medicine) and medical treatment will be extremely useful to: herpes eruptions of cures and control, viral diffusions, extended periods and latency of diseases, and drastically inhibit viruses, while they are generally safe to the patient and the environment.

A more detailed explanation of the invention is given in the following description and the appended claims.

DETAILED DESCRIPTION OF THE PREFERRED MODALITIES A herpes virus microbicide and a treatment are provided to relieve pain, heal lesions, resolve infectious rashes quickly and inhibit the herpes simplex virus 1 and 2 (HSV 1 and HSV 2). Conveniently, the herpes microbicide and treatment completely inhibit the herpes virus, as well as other infectious microbial diseases, and are safe and non-toxic to humans, animals and the environment. The herpes microbicide and the medicine may comprise a surfactant and a herbal botanical that provides a botanical, phytochemical, antimicrobial isolated, viral isolate, microbial inhibitor and viral inhibitor extract. The preferred microbicidal composition may comprise: a surfactant; an aqueous diluent and the herbaceous botanical substance of the Echinacea (E) genus, of the Asteracea family, species: purpurea, angustí folia, pallidae, vegetalis, atribactilus and the cultivated species. Preferably the herbaceous botanical substances are extracts and isolates comprising Echinecea phytochemicals as found and extracted from Echinoacea purpurea, E. pallidae and E. angusto folia. For best results, medical treatment and microbicide (medicine) include: a cationic surfactant; the phytochemicals of - ?. purpurea and E. angustofolia and a sterile aqueous diluent. The surfactant provides some debridement of epithelial cells are a broad spectrum of antimicrobial action. Surfactants of this nature may comprise quaternary ammonium salts containing from 6 to 18 carbon atoms. Preferably the surfactant agent of the quaternary ammonium salt is a mixture of dimethylbenzylammonium chlorides of alkoxy, which may be: a benzalkonium halide, benzalkonium bromide, benzalkonium chloride and more preferably benzalkonium chloride. The herpes treatment comprises a 100% active aqueous solution, but it can also be used in a concentrate. The solution may comprise, by weight, various concentrations of surfactants, such as from 0.005 to 0.8%, preferably from 0.02 to 0.30% and more preferably from 0.02 to 0.26%. The phytochemicals in botanical Echinacea have shown great activity against bacteria, viruses and some fungi. The exact mechanism is unknown. When tested topically in vivo in HSV 1 and 2, it is somewhat effective in treating infectious herpes simplex rashes. When tested in vitro they showed some inhibitory activity against HSV 1 and 2. The composition of the phytochemical concentrate comprises the following isolated constituents, botanical extracts, microbial inhibitors and antimicrobial isolates: polysaccharides, equinacein, equinacein, echinacoside (esters of caffeic acid), equinolone, equinadiol, enzymes, glucuronic acid, inuloid, pentadecadiene, polyacelylene compounds, arabinogalactan, rhamnose, PS I (a 4-0- ethylglucoronarabinoxylan, Mr 35 kD) and PS II (a non-arabinogalactam acid, Mr 450 kD), cynarin (1,5-di-0-caffeoylquinic acid), (2,3-0-dicaffeoyltartaric acid) and derivatives , alkylamides, ketoalkynes and alkanes; quinones, aeites, which include borneol, bornyl acetate, pentadeca-8 (z) -en-2-one, germacrene D, caryophyllene, caryophyllene-epoxide, anthocyanins-pyrrolizidine-alkaloids, lipophilic amides, isobutylamide, polyacetylenes. For best results, the antimicrobial isolates of the phytochemical concentrate comprise, by weight (based on the total weight of the medical composition of the invention): from 0.3 to 9% equinacosides; from 0.1 to 7% of PS I (a 4-0-methylglucoronoarabinoxylan, Mr 35 kD), and PS II (an acid rhamnoarabinogalactan, Mr 450 kD); from 0.1 to 10% of cyanarin (l, 5-di-0-caffeoylquinic acid) and acid (2,3-0-di-caffeoyltartaric acid) and their derivatives; from 0.2 to 4% of equinolone, from 0.2 to 8% of equinacin B; from 0.1 to 6% equinacein; from 0.2 to 7% of anthocyanins comprising 3-0-β-D-glucopyranoside of cyanidin and 3-0- (6-0-malonyl-β-D-glucopyranoside); from 0.01 to 0.06% of pyrrolizidine-alkaloids, which include tusilagina and isotusilagina; from 0.003 to 0.009% of isomeric dedecaisobutylamides and 2E, 4E, 8Z, lOE / Z-tetraenoic acid; and from 0.01 to 2% of Cariopilians. The phytochemical concentrate may comprise, by weight: from 2 to 90% of the medical composition and solution and preferably comprises not less than 15% of the composition and solution; and, for best results, it comprises 40 to 60% of the medical composition and solution. The diluent dissolves the benzalkonium chloride (surfactant) and the phytochemical concentrates and can act as a carrier in drips, tubes and drip bottles. The preferred diluent is an aqueous diluent and more preferably is a sterile aqueous diluent. The reversion of water in the aqueous solution to benzalkonium chloride can vary from 30,000: 1 to 250: 1 and preferably, in topical application, from 5,000: 1 to 750: 1. The ratio of the water to the combined benzalkonium chloride concentrates and phytochemicals can comprise a range of 2: 1 to 100: 1, with a preferred range of 4: 1 to 40: 1 and, for best results, can comprise a ratio of 6: 1 to 20: 1. For better results, the improved microbicidal treatment and medicine for herpes comprises, by weight: 0.02 to 0.3% of the benzalkonium chloride and, to avoid toxicity, preferably less than 0.26%; from 40 to 60% of Echinacea phytochemicals; and from 20 to 60%, more preferably from 29.74 to 59.8% of sterilized water. While water is the preferred diluent and carrier, it is more convenient, in some circumstances, to use other carriers, in order to drive the concentrate through a sprayer, or for greater solubility and efficiency, it may also be desirable, in some circumstances , include a viscosity control agent. Also, while it is estimated that the shelf life of improved herpes medicine is two years, it may be necessary to add an appropriate condom. For your preferred use, during any eruption or physical manifestations of herpes and preferably at the first sign of the prodrome stage of itching, itching or irritation of herpes, the medical solution (medicine) should be applied topically on the infected area. The affected (infected) area should be as dry as possible, depending on the location of the rash. The method of topical application of the medicine can be by: spraying, smearing, dripping or any method to cover the entire affected area. The coating of the solution (medicine) must be maintained until all the external symptoms are completely resolved, the reapplication, as necessary, the coating decreases, for example, after the shower. Anionic soaps and anionic detergents, and especially soaps containing proteins, may be contraindicated. Preferably, the infected area should be washed, cleaned and dried before application of the medicine.

CLINICAL PHARMACOLOGY A preferred surfactant is benzalsonium chloride. This benzalkonium chloride in aqueous solution is commercially available under the trade name of Zephiran®, distributed by Sanofi Winthrop Pharmiceutisals (formerly Winthrop Labs). Benzalsonium slurry is a fast-acting, anti-infection, tensoastive agent with a moderately long duration of action. The surfactant is useful against bacteria and some viruses, fungi and protozoa: the spores of bacteria are considered to be resistant. Benzalkonium chloride solutions are bacteriostatic or bacteriocidal, according to the concentration. The exact mechanism of bacterial action of benzalkonium chloride is unknown, but is thought to be due to enzyme inactivation. The activity of benzalkonium chloride generally increases with increasing temperatures and pH. Gram-positive bacteria are more susceptible to benzalkonium chloride than Gram-negative bacteria. Unfortunately, benzalkonium chloride is inactivated by soaps, anionic detergents, serum and certain proteins. This benzalkonium chloride is not used by many laboratories for the above reasons. When benzalkonium chloride is used alone and is tested topically in vivo, it is not effective for herpes simplex infectious rashes. When tested in vitro in HSV 1 and 2, benzalkonium chloride demonstrated high inconvenient levels of toxicity to cells, even at high dilutions, which is not moderately acceptable. The chemical formula of a type of benzalkonium chloride is shown below. Other types of benzalkonium chloride can be used. benzalkonium chloride While raw Echinacea, untreated, unprocessed, not isolated, is not generally suitable for treating herpes, it has been found that some, not all, of the isolated constituents and botanical extracts of Echinacea (as previously described) provide phytochemicals, antimicrobial isolates, botanical extracts and microbial inhibitors, which are effective in treating the herpes virus and other infectious diseases. As previously noted, the concentrated phytochemical composition comprises the following isolated constituents, botanical extracts, microbial inhibitors and antimicrobial isolates: polysaccharides, echinacene, equinacein, echinacoside (ester caffeic acid), equinolone, equinadiol, enzymes, glucuronium acid, inuloid, pentadecadiene. , compounds of polyacelylene, arabinogalactan, rhamnose, PS I (a 4-0-methylglucoronoarabinoxylan, Mr 35 kD) and PS II (a ramnoarabinogalactan acid, Mr 450 kD), cynarin (1,5-di-O-caffeoylquinic acid), acid (2,3-0-di-caffeoyltartaric), and its derivatives, alkylamides, keto-alkynes and -alkenes; quinones; oils that include: borneol, bornyl acetate, pentadeca-8 (z) -en-2-one, germacrene D, caryophyllene, caryophyllene-epoxide, anthocyanin-pyrrolizidine alkaloids, lipophilic amides, isobutylamides, polyacetylenes. The chemical formula of some botanical extracts of Echinacea are shown below.

When the Echinacea phytochemicals (antimicrobial isolates, botanical extracts and microbial inhibitors) are mixed, combined and applied with a surface active agent, preferably benzalkonium chloride, and a sterile aqueous carrier, the results were unexpected and surprisingly good, in resolving ( treat) the herpes virus and other infectious diseases and the effectiveness of the medicine (microbicide) increased drastically. When the synergistic medicine was tested topically in vivo, the herpes simplex infections stopped immediately. When the synergistic medicine was tested in vitro, the benzalkonium chloride surfactant was substantially less toxic and within a level of safety and there was a higher level of inhibitory activity against HSV 1 and 2. The interaction of syncretism and mixture of Echinacea phytochemicals and surfactant was demonstrated and observed by the rapid solubility of the components, when mixed and the slight quality of adhesive created by the properties in solution. Also, the chemical properties of the Echinacea phytochemicals, surfactant and aqueous carrier intensify the stabilization and increased reactivity that is useful in treating infectious diseases. The medicine can be used in several dilutions in: the oral and nasal mucosa; vaginal tissue, labial tissue; anal and peri-anal tissue; penis tissue; cutaneous tissue; open subcutaneous tissue; and in higher dilutions in ocular infections. By varying the concentrations, the medicine can possibly be administered parenterally. The medicine can be contraindicated in vaginal or anal compresses; in the anal of the ear; occlusive bandages; Masks or ingestion and such use may cause irritation or chemical burns. It may not be advisable to use the medicine to treat anaerobic fungal infections, since some fungi may be resistant.

EXAMPLES 1 TO 7 IN VIVO TESTS In an initial topical application, a live ip study was carried out to evaluate the effects of the medical treatment and the medicine of the present invention on seven human test subjects, who had been tested positive for HSV 1 or 2. The subjects were treated topically with the medicine comprising the benzalkonium chloride surfactant in an aqueous solution (at a ratio of 1: 750), in combination with Echinacea purpurea herbaceous botany, in powder form, containing the phytochemicals listed previously. The application of the composition was done by a two-stage process by first soaking the affected area or vesicle with the benzalkonium chloride surfactant, in an aqueous solution, by spraying, anointing or using a dropper; then applying a coating of the phytochemical powder on the soaked area by rubbing or manually spraying the powder over the infected area. An important aspect of this treatment is to maintain full coverage of the affected area for the duration of the eruption. Therefore, the area of the eruption remained covered with the medical composition by reapplication, as necessary. Of the seven subjects, six were women and one man. At the beginning of this study, the age of the man was 38 years, and the ages of the women were 8, 27, 30, 32, 38 and 39 years. There were twelve infectious rashes in about six weeks. Nine of the rashes were HSV 2, genital herpes, and three were HSV 1, cold rashes. Women 8 and 27 years old exhibited HSV 1 (cold rashes). The women of 30, 38 and 39 years of age exhibited HSV 2 (genital herpes). The 38-year-old also had a cold HSV 1 rash. The man exhibited HSV 2 (genital herpes). All tested subjects had a well-established history of the disease and could identify the standard course of their disease. To obtain objective data, none of the test subjects knew anything about the test treatment and any action of the medicine. When repeating the tests, the subjects were told that there were mixed placebos in the formula samples. In seven cases, the antimicrobial compound (medicine) was applied directly on the tissue at the prodrome stage. In five cases, the antimicrobial compound was applied directly on the vesicles with rash. The antimicrobial compound was reapplied, as necessary, to maintain coverage. Observations: with each application of the medicine, each individual (test subject) reported an itching sensation for a few seconds. They also reported that there was a substantial degree of adherence of the medicine (antimicrobial compound) to the vesicle (s) or affected area. The adhesion of the composition to the epithelial tissue remained to a degree even after showering or rinsing with water from the area. Results: The results of the test of the 7 subjects with the medical treatment and the medicine were unexpectedly surprisingly good and very consistent. In each case, the subject reported fortunately that once the composition (medicine) was applied to the affected area, the pain completely stopped within 10 to 20 minutes, when nothing in the past had mitigated the pain. In all seven cases, where the compound (medicine) was applied in the prodrome stage, the subjects reported that the pain was stopped, all the symptoms that had been previously escalated until the complete eruption ceased and the rash never occurred. All external symptoms and physical manifestations of herpes disappeared within a few hours after applying the medicine. In the five cases, where the compound (medicine) was applied to vesicles with rash, the subjects reported that the pain stopped in minutes and the burn, itching and irritation resolved in two to four hours and the vesicles dried up and disappeared in twenty-two hours In all cases, the other more extreme symptoms, of weakening of: fever, malaise, inguinal swelling, eruption with draining and painful action when urinating, were resolved once the medicine was applied. In the follow-up, when the subjects were supplied with the composition (medicine) for the test in future eruptions, it was reported that if the initial signs of an eruption were exhibited, which indicated the prodrome stage of an eruption, the compound (medicine) it was applied immediately by the subjects, according to the instructions, and the rash stopped completely and subsequent symptoms never occurred. Significantly, it was also reported by subjects who were accustomed to experiencing several eruptions annually, that they had markedly longer latency periods. In a three-year follow-up, an individual, who had reported severe rashes monthly for four years before using this medicine, now reported that he had not had rashes in more than a year since using this medicine. Additional Observations: a male human subject, reported that after the initial application, during the prodrome phase of an eruption, he took a shower and forgot to re-apply the composition (medicine) for a period of approximately 30 hours. Consequently, several vesicles sprouted and began to coalesce. The subject proceeded to re-apply the somposition (medicine) and then kept the area well covered with the composition. Next, the eruption resolved in 21 hours, in the same way as described with the other human subjects. Another observation indicated that the composition (medicine) may be weakened or less effective in the presence of certain proteins or soaps. A female human subject may have been excessively jealous in cleaning the affected area prior to the application of the composition (medicine). This occurred during a tersera eruption after having succeeded with the composition (medicine) in two previous eruptions. In this case, when the composition was applied (medicine), there was no sensation of familiar itching and there was no relief from the symptoms. Approximately 24 hours before seeking advice and the rash had escalated to the full stage of vesicular eruption, with all the previous symptoms of the disease. He was instructed to thoroughly rinse any soap residue from the area, dry the area and reapply the composition (medicine). After following the instructions, he reported that the eruption resolved completely, as in the two previous eruptions, after applying the medical composition.

EXAMPLES 8 TO 13 DERMATOLOGICAL AND VETERINARY TEST Animal tests were performed to determine any possible allergic dermatological reaction induced by the medical composition (medicine). Six animal subjects were used. The animals included 3 female rabbits (unknown ages), 2 dogs (1 female, 2 years old, and 1 male, 9 years old), a male cat, capon, 3 years old. In these tests on animals, the previous composition (medicine) was applied in the method indicated previously, to the interior of the external area of each animal. In all cases, the area that is. will treat was kept covered with the compound for twenty-four hours, which corresponds to the time used by human subjects. The tests performed on the six animal subjects indicated that there were no signs of dermatological irritation or allergic reaction. EXAMPLE 14 The above medical compound, which contains viral inhibitors, was also tested on the warts caused by the papilloma virus, on the muzzle of a two-year-old gelding. Warts of the papilloma virus are difficult to treat. The wart was 25 mm in diameter. The antimicrobial compound (medicine) was applied twice daily. This wart was then measured in each application. Results: Very unexpectedly, the wart decreased drastically in size by approximately 3 mm per day, while the medicine was applied to this wart and on the fifth day it was completely detached. It was observed that in the first superficial layers of the wart they began to degrade, exposing large erythematous papules. Then, interestingly, the warts did not diminish just in size due to the formation of flakes or detachments, they decreased at the point of attachment in the epidermis of the subject and separated and fell intact without scar sequels.

In progress, the long-term in vivo study of this invention, which began with the first seven subjects in April 1898 and has now spread for 7 years, approximately 100 infectious rashes have been treated with medicine in different concentrations, such as It was described as a pre-event. In all cases, surprisingly good results were the same: 1. disappearance of pain in minutes; 2. No eruptions occurred when the composition was applied in the prodrome stage; 3. The eruptions resolve in twenty-one hours when applied in the vesicular stage; 4. Longer periods of latency or without subsequent eruptions.

IN VITRO TESTS Laboratory tests were undertaken at the University of Chicago, Clinical Laboratories of Microbiology, to determine the in vitro inhibitory activity of medical treatment and composition (medicine). The laboratory test was conducted by Associate Director, PhD, and Associate Professor of Pathology. The in vitro test of the medical composition, immediately called the "Drug", provided surprisingly good results. It was determined that medical treatment and composition, unexpectedly, provided excellent inhibitory activities, in HSV 1 and HSV 2. It was pointed out by the pathologist that he had tried "hundreds" of other compounds and had never seen a product as good as this compound. The following are the tests of the medicine that were conducted and the results that were obtained at the University of Chicago. For ease of interpreting some of the scientific data and test results, the following definitions apply: "MEM" refers to the Minimum Essential Medium. That is, the culture medium used in laboratories to grow the cells in which the tests were performed. "Fibroblast" is a mesenchymal human cell (a cell found in connective tissue, blood, bone, lymph and cartilage). "IC50" refers to the Inhibition Concentration. For this test, a 50% endpoint was selected, as is typical. The next number indicates the highest dilution below 50%. Therefore, it is the definition of the endpoint. If an area under a dilution is left blank, it indicates that there may have been toxicity in that dilution, the test has not had a valuable reading or interpretable data are not available. If an area under dilution has been marked with a dash (-), this indicates that there are no plaques and there is a total successful inhibitory activity.

EXAMPLES 15 TO 18 In these in vitro tests, the following drugs (composition) were used: Drug # 1 = benzalkonium chloride surfactant, in an aqueous solution at a ratio of 1_750. The surfactant in the aqueous solution was filtered after use and diluted in an equal volume of 2x MEM to give a dilution of 1: 1500 in IX MEM. Drug # 2 = Echinacea powder (phytochemicals) in an aqueous solution. This preparation was extracted by hot infusion in sterile water. The extracted phytochemicals were centrifuged and filtered before use. The filtered phytochemicals were diluted in an equal volume of 2X MEM to give the preparation undiluted in IX MEM. Drug # 3 = Echinacea powder (phytochemical) was extracted and combined with the surfactant benzalkonium chloride agent by a cold infusion process. The combined preparation was subjected to centrifugation and filtered before use and diluted in an equal volume of 2X MEM to give the undiluted preparation in IX MEM. 1. Three 24-compartment plates were inoculated with fibroblasts. Three different extractions (for comparison) in five concentrations of the composition were used to classify the antiviral activity at concentrations of: undiluted, 1: 2, 1: 4, 1: 8 and 1: 6 in IX MEM. There were four control compartments in each plate, which contains the MEM without drug. 2. The growth medium was removed from the compartments and 200 μl of HSV-1 was added to each compartment of the upper half of each plate. HSV-1 was diluted 1_5000 (2.0 μl of HSV-1 product in 10 ml of MEM). The virus titer was 3x10 ^ per ml. Similarly, 200 μl of HSV-2 was added to each compartment of the upper half of each plate. The HSV-2 was diluted 1: 2,000 (5.0 μl of HSV-2 product in 10 ml of MEM). The virus titer was 6xl05 per ml. 3. Plates were incubated at 372C for two hours. 4. The inoculum was removed and one ml of MEM containing Drugs # 1-3 was added to the four compartments. The concentration of the drug compared to the MEM is indicated below.

Table 1 Concentration Undiluted 1: 2 1: 4 1: 8 1: 16 Drug (μl) 4000 2000 1000 500 250 MEM (μl) - 200 3000 3500 3750 . Results: HSV-1, liquid superimposed, Drug added immediately after virus absorption. Plate 1, Drug # 1, contaminated with bacteria! Without growth, there can be debris. Plate 2, Drug # 2 contaminated with bacteria! Without growth, there may be waste. Plate 3, Drug # 3. The results are indicated in Tables 2 and 3 below.

Table 2 - Test Results, Drug # 3 H3V-1 Concentration Undiluted 1: 2 1: 4 1: 8 1: 16 plates 54 toxic toxic 6 * 12 ** plates 42 toxic toxic 4 * 16 ** Average 48 14 14 Cl 50 > 1:16 Table 3 - Test Results, Drug # 3 HSV 2 Concentration Undiluted 1: 2 1: 4 1: 8 1:16 plates 46 toxic toxic - 22 * 32 ** plates 59 toxic toxic - 21 * 28 *** Average 48 22 30 30 Cl 50 = 1. 8 * mild toxicity ** very small plates. Comments: The tests with the medicine (Drug # 3) provided excellent results. The cells were observed fine without contamination. At minor dilutions, the preparation can be toxic to some of the cells. This preparation was unexpectedly successful in its inhibitory activity. EXAMPLES 19 to 22 Three 24-compartment plates were inoculated with fibroblasts and the following drugs. Test Drug @ 1A = benzalkonium chloride surfactant in an aqueous solution. The benzalkonium chloride surfactant was prepared by making a dilution of 1: 375 in water (32 μl in 12.0 ml of sterilized water). This is filtered before use. It was diluted in an equal volume of 2X MEM to give a 1: 750 dilution in IX MEM. The dilution was made to maintain the relationship.

Test Drug # 2A = Echinacea purpurea powder (phytochemical) in an aqueous solution. This preparation was a 50 mg / ml solution (300 mg in 6.0 ml of water) of Echinacea purpurea powder in sterilized water. The mixture was stirred and refrigerated for four hours. The Echinacea powder preparation was centrifuged at 3500 rpm for 15 minutes at 10 seconds and filtered before use and then diluted in an equal volume of 2X MEM to give the preparation undiluted in IX MEM. Test Drug # 3A = Echinacea purpurea powder ) phytoc [uimic), dissolved in benzalkonium chloride surfactant. This preparation was a 50 mg / ml solution (300 mg in 6.0 ml of benzalkonium chloride, 1: 375). The mixture was stirred and refrigerated for four hours. The mixture of phytochemical and tesactive agent was centrifuged at 3500 rpm for 15 minutes at 10 ° C and filtered before use and then diluted in an eqvolume of 2X MEM to give the preparation undiluted in IX MEM. 1. Three plates were used to classify the three drug preparations. The concentrations necessary to classify the antiviral activity were 1: 2, 1: 4, 1: 8 and 1:16 in IX MEM. There were 4 control compartments in each plate, with MEM and no drug. 2. The growth medium was removed from the compartments and 200 μl of HSV-1 was added to each compartment of the upper half of each plate. The HSV-1 was diluted 1: 5000 (3.0 μl of the HSV-1 product in 10 ml of MEM). The virus titer was 3 x 106 per ml. 3. The plates were incubated at 37sc for four hours. 4. The inoculum was removed and one ml of MEM, containing drugs # 1A-3A, was added to the four compartments.

Table 4 Concentration Undiluted 1: 2 1: 4 1: 8 1: 16 Drug (μl) 4000 2000 1000 500 250 MEM (μl) 2000 3000 3500 3750 . Results: Composition, liquid, superimposed HSV-1, added immediately after virus uptake.

Table 5 - Drug # 1A - HSV l. Test Results Concentration 1: 2 1: 4 1: 8 1:16 1:32 Plates 70 toxic toxic toxic toxic toxic Plates 68 Plates 58 Plates 74 Average 70 CT-50 Comments: These compartments have a fine precipitate on the cells. Benzalkonium chloride probably precipitates with the protein in the medium.

Table 6 - Drug # 2 - HSV 1, Test Results Concentration 1: 2 1: 4 1: 8 1:16 1:32 Plates 72 9 * 12 * Plates 74 7 8 Plates 79 4 12 Plates 71 7 11 Average 70 IC50 > 1:32 Comments: Although there are some plates, they were very small.

Table 7 - Drug # 3A - HSV 1. Test Results Concentration 1: 2 1: 4 1: 8 1:16 1: 32 Plates 72 toxic toxic toxic toxic - * Plates 68 Plates 67 Plates 70 Average 70 IC50 > 1:32 Comments: Although there is some toxicity, this drug was very successful in inhibiting the virus, it does not appear to be any plaque.

EXAMPLES 23 TO 27 Four plates of 24 compartments were inoculated with fibroblasts. Test Drug # 1B = Benzalkonium chloride surfactant in an aqueous diluent. The benzal-conium chloride was prepared by obtaining a dilution of 1: 1000 in water (10 μl in 10.0 ml of sterile water). This was filtered before use and diluted in an eqvolume of 2X MEM to give a 1: 2000 dilution in IX MEM (500 μl of drug plus 500 μl of 2X MEM). Test Drug # 2B = Echinacea purpurea powder (phytochemical) in an aqueous solution. This preparation was a 50 mg / ml solution (250 mg in 5.0 ml of water) of Echinacea purpurea powder in sterile water. The mixture was vortexed and refrigerated for four hours. This preparation of Echinacea powder was centrifuged at 3500 rpm for 15 minutes, at 10 ° C, and filtered before use, and diluted in an eqvolume of 2X MEM, to give the preparation undiluted in IX MEM (500 μl of drug plus 500 μl of 2X MEM). Test Drug # 3B = Echinacea purpurea powder (phytochemical) dissolved in the benzalkonium chloride surfactant. This preparation was a 50 mg / ml solution (250 mg in 5.0 ml benzalkonium chloride, 1: 1000). The mixture was vortexed and refrigerated for four hours. The phytochemicals of Echinacea and surfactants were centrifuged at 3500 rpm for 15 minutes, and then filtered before use, and diluted in an eqvolume of 2X MEM, to give the preparation in IX MEM (500 μl of drug plus 500 μl of 2X MEM). Test Drug # 4B = Echinacea purpurea powder (phytochemicals) in an aqueous solution (diluent) and then mixed with the benzalkonium chloride surfactant in a ratio of 1: 1000. This preparation was a 50 mg / ml solution (250 mg in 5.0 ml of water) of the Echinacea purpurea powder in sterile water. This mixture was vortexed and refrigerated for four hours. The aqueous phytochemicals were centrifuged at 3500 rpm for 15 minutes, at 102 ° C and filtered before use. This preparation was diluted in an equal volume of benzalkonium chloride at a ratio of 1: 1000, to obtain the Echinacea-benzalkonium chloride mixture. This mixture was diluted with an equal volume of 2X MEM to give the 1: 4 preparation in IX MEM (500 μl of Drug # 1 and 250 μl of Drug # 2 plus 500 μl of 2X MEM). 1. Four plates were used to classify the four preparations of the drug. The concentrations needed to screen the antiviral activity were 1:20, 1:40, 1:80 and 1: 160 and 1: 320 in IX MEM. There are four control compartments on each plate containing MEM without the drug. 2. The growth medium was removed from the compartments and 200 μl of HSV-1 was added to each compartment of the two upper rows of each plate. HSV-1 was diluted 1: 5000 (2.0 μl of HSV-1 product in 10 ml of MEM). The virus titer was 3xl06 per ml. Similarly, 200 μl of HSV-2 was added to each compartment of the lower half of each plate. The HSV-2s diluted 1: 2,000 (5.0 μl of the HSV-2 product in 10 ml of MEM). The virus titer was 6 ml. 3. Plates were incubated at 37SC for four hours. 4. The inoculum was removed and one ml of the MEM containing Drugs # 1-4 was added to the four compartments.

Table 8 Concentrated 1:20 1:40 1:80 1: 160 1: 320 Drug (μl) 400 200 100 50 25 MEM (μl) 3600 3800 3900 3950 3975 Results: HSV-1, liquid superimposed, the drugs were added immediately after the absorption of the virus.

Table 9 - Drug # 1B - HSV l. Test Results Concentration 1:20 1:40 1:80 1: 160 1: 320 Plates 37 toxic toxic toxic toxic 15? Plates 45 18? Average 41 I50 Comments: Slightly toxic, the test was difficult to read. HSV-2, superimposed liquid, the drugs were added immediately after the absorption of the virus.

Table 10 »Drug # 1B - HSV 2. Test Results Concentration 1:20 1:40 1:80 1: 160 1: 320 Plates 38 toxic toxic toxic toxic 21 Plates 42 17 Average 40 19 IC50 > 1: 320 Comments: The test was too toxic to give a good reading.

Table 11 - Drug # 2B - HSV 1. Test Results Concentration 1:20 1:40 1:80 1: 160 1: 320 Plates 39 2 * 8 * 23 * 24 44 Plates 40 3 18 11 28 38 Average 40 3 13 17 26 IC50 > 1:80 Comments: Small plates Table 12 - Drug # 2B - H8V 2. Test Results Concentration 1:20 1:40 1:80 1: 160 1: 320 Plates 48 21 33 Plates 52 22 38 Average 50 21.5 35.5 IC50 > 1:20 Table 13 - Drug # 3B - HSV 1, Test Results Concentration 1:20 1:40 1:80 1: 160 1: 320 Plates 44 1 * 17 31 37 Plates 46 - 16 28 27 Average 45 _ 17 30 32 IC50 > 1:40 Comments: Although there was some toxicity, the drug very successfully did not appear to be on any plate.

Table 14 - Drug # 3B - HSV 2. Test Results Concentration 11 :: 2200 11 :: 4400 11 :: 8800 11 :: 116600 1: 320 few cells 11 * 27 30 35 Plates 44 10 32 Average 44 11 29. 5 IC50 > 1:20 Comments: A difficult test to obtain a really good reading. However, the drug had a successful inhibitory activity.

Table 15 - Drug # 4B - HSV 1. Test Results Concentration 1:40 1:80 1: 160 1: 320 1: 640 Plates 47 toxic toxic toxic 33 Plates 48 28 Average 48 30 IC50 > 1: 320 Comments: Toxic to higher levels. However, there was an inhibitory activity at 1: 320.

Table 16 - Drug # 4B - HSV 2. Test Results Concentration 1:40 1:80 1: 160 1: 320 1: 6420 Plates 38 Toxic toxic toxic 2 * 16 Plates 40 4 20 Average 39 3 18 IC50 > 1: 640 Comments: The toxicity is probably due to benzalkonium chloride. The drug at a dilution of 1: 320 showed a very strong inhibitory activity. The in vitro tests of Examples 23-27 used raw materials that were not refined. However, the tests showed, surprisingly, good inhibitory activity and a probable synergy between the constituents. In previous in vitro tests, where the Drugs # 3, 3A and 3B, were phytochemicals of Echinacea purpurea extracted and combined with the surfactant agent of benzalkonium chloride, the resulting medicine showed greater antiviral activity and more remarkably demonstrated a synergy between the components: Echinacea purpurea and benzalkonium chloride. This can possibly be explained by a shared stability and increased reactivity between the two components. The benzalkonium chloride in the synergistic mixture exhibited a lower degree of toxicity and the synergistic combination (medicine) exhibited a higher degree of antiviral activity, particularly with HSV-2.

TENSITIVE AGENTS While benzalkonium chloride is the preferred surfactant for best results, in some circumstances it may be convenient to use other quaternary ammonium surfactants or other surfactants. The quaternary ammonium compound can be dicoco-diammonium chloride, which is also known as dicoco-alkyldimethyl chloride or dicoco-dimethylammonium chloride or Di-C8-18-alkyldimethyl chlorides. This can be used in combination with isopropanol, such as 20-30% iso-propanol. The preferred source of the quaternary compound comprises: 70-80% of the quaternary ammonium compound and less than 0.03% of methyl chloride, has a specific gravity of approximately 0.87 to 462C, a vapor pressure of 33 mm / Hg at 202C, an initial boiling point of 82 ° C to 760 mm / Hg, and a volatility of 20-30%, and produced under the trade name CarSpray 300 by Witco Corporation, Dublin, Ohio, USA, This quaternary compound can provide disinfectant qualities and serve as a fungicide to treat fungal and yeast infections.

Other quaternary ammonium compounds may be useful, such as those produced under the tradename Jet Quat 2C-75 by Jeteo Chemicals, Inc., of Corsicana, Texas, USA, or produced under the trade names of Carspray 400 and Carnauba Spray 200 by Witco Corporation, Dublin, Ohio, USA, or containing 9% denatured ethyl alcohol, such as that sold under the tradename BTC 2125M by Stephan Company, of Northfield, Illinois, USA, or the following MAQUAT products, which comprise n-alkyl-dimethyl-benzyl-ammonium chloride, produced by Mason Chemical Company, of Arlignton, Heights, Illinois, USA, LC-12S (67% C12, 25% C14, 7% C16, 1% C18), MC 1416 (5% C12, 60% C14, 30% C16, 5% C18), MC1412 (40% C12, 50% C14, 10% C16), stearite paste or flakes SC-18 (5% C16, 95% C18) ), TC-76 OR MQ-2525 (5% C12, 60% C14, 30% C16 and 5% C18) and MC6025-50% (25% C12, 60% C14 and 15% C16). Jet Quat 2C-75 comprises: 50.-75% dicoco-dimethyl-ammonium quaternary chloride, 20-50% isopropyl alcohol, has a specific gravity of 0.88 and a boiling point of 82. The CarSpray 400 comprises: 55 -65% of quaternary ammonium compounds, 20-30% of amines, C14-18 and C16-18 unsaturated alkyls, ethoxylates, 10-20% isopropanol and less than 0.03% methyl chloride, and has a specific gravity of about 0.88 to 24dC, a vapor pressure of 33 mm Hg at 202C, an initial boiling point of 822C at 760 mm Hg and a volatility of 10-20%. Carnauba Spray 200 comprises: 50-60% quaternary ammonium compounds, 10-20% isopropanol, 15-25% water, 1-10% alkoxylated carnauba wax and less than 0.03% methyl chloride, and it has a specific graved from approximately 0.90 to 26.62C, a vapor pressure of 33 mm Hg at 202C and an initial boiling point of 822C at 760 mm Hg, and a volatility of 20-40%. Nonionic surfactants are surface active compounds that do not ionize in the water solution. Often having hydrophilic characteristics by virtue of the presence of an oxygenated chain (for example, a poly-oxyethylene chain), the lipophilic portion of the molecule is derived from fatty acids, phenols, alcohols, amides or amines. Exemplary compounds are the condensates of poly (ethylene oxide) of alkyl phenols, for example the condensation product formed of one mole of nonyl phenol and ten moles of ethylene oxide, and the condensation products of aliphatic alcohols and ethylene oxide, for example the condensation product formed of 1 mol of tridecanol and 12 mol of ethylene oxide. The nonionic surfactants may comprise ethoxylates of phenol including the condensation product of ethylene oxide and an alkylphenol, or an aliphatic alcohol. The nonionic surfactants preferably comprise the ethoxylate of nonophenol, such as T-DET and / or ethoxylate of octaphenol. The nonionic surfactants are the reaction products of ethylene oxide and nonolfenol and / or octalphenol. The ratio of phenol to ethylene oxide can vary from 2:20 to 4: 16 and preferably is 8:12. Synthetic surfactants may comprise nonionic detergents. The synthetic nonionic surfactants can also be formed by the condensation of ethylene oxide with a hydrophobic base, formed by the condemnation of propylene oxide with propylene glycol. The hydrophobic portion of the molecule, which, of course, exhibits insolubility in water, has a molecular weight of about 1200 to 2500. The addition of the polyoxyethylene radicals to this hydrophobic portion tends to increase the water solubility of the molecule as a total and the liquid charaster of the product can be retained to the point where the polyoxyethylene content is about 50% of the total weight of the condensation product. Other synthetic non-ionic surfactants may include: polyethylene oxide condensates of alkylphenols, for example the condensation products of alkylphenols or dialkylphenols, in which the alkyl group contains about 6 to 112 carbon atoms in any straight or branched chain configuration, with the ethylene oxide. This ethylene oxide may be present in equal amounts of 8 to 25 moles of ethylene oxide per mole of alkylphenol. The alkyl substituent in such compounds can be derived from the polymerized propylene, diisobutylene. n-octene or n-nonene. Nonionic surfactants can also be produced from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylenediamine, for example compounds containing about 40 to 80% of the polyoxyethylene by weight and having a molecular weight from about 5,000 to 11,000, resulting from the reaction of the ethylene oxide groups with a hydrophobic base, which comprises the reaction product of the ethylene diamine and the excess propylene oxide.; the base has a molecular weight of the order of 2,500 to 3,000. Other nonionized surfactants include the condensation product of aliphatic alcohols having 8 to 18 carbon atoms, in any straight or branched chain configuration, with the ethylene oxide, for example a condensation product of coconut alcohol and the ethylene oxide, having from 10 to 30 moles of ethylene oxide per molecule of coconut alcohol, and the fraction of coconut alcohol having from 10 to 14 carbon atoms. Additional nonionic surfactants include the long chain tertiary amine oxides, corresponding to the following general formula: R1R3R2N? 0 where R ^ is an alkyl radical with 8 to 18 carbon atoms and R2 and R3 are each methyl or ethyl radicals. The arrow in the formula is a conventional representation of a semi-polar link. Examples of amine oxides suitable for use include: dimethyldodecylamine oxide, di-methyloctylamine oxide, dimethyldecylamine oxide, dimethyltetradecylamine oxide and dimethylhexadecylamine oxide. Other nonionic surfactants may include the long chain tertiary phosphine oxides corresponding to the following general formula: RR 'R "P -» O wherein R is an alkenyl or monohydroxyalkyl radical, having from 10 to 18 atoms of carbon in the chain length, and R 'and R "are each alkyl or monohydroxyalkyl groups, containing from 1 to 3 carbon atoms. The arrow in the formula is a conventional representation of a semi-polar link. Examples of suitable phosphine oxides are: di-ethyldodecylphosphine oxide, dimethyltetradecylphosphine oxide, ethylmethyltetradecylphosphine oxide, cetyldi ethyl-phosphine oxide, dimethyl stearylphosphine oxide, cetylethylpropylphosphine oxide, diethyldodecylphosphine oxide, diethyltetradecylphosphine oxide, dipropyldodecylphosphine oxide , bis- (2-hydroxymethyl) -dodecylphosphine oxide, bis- (2-hydroxyethyl) dodecylphosphine oxide, (2-hydroxy-propyl) methyltetradecylphosphine oxide, dimethylolylphosphine oxide and dimethyl- (2-hydroxydecyl) phosphine oxide. In some circumstances, it may be useful to use other surfactants, such as: other cationic surfactants, an ampholytic surfactant or an ambiguous surfactant. The surfactants may include cationic detergents. These cationic surfactants comprise compounds that ionize in an aqueous medium to give cations containing a lipophilic group. Typical of these compounds are the quaternary ammonium salts containing an alkyl group of about 12 to 18 carbon atoms, such as lauryl-benzyl-dimethyl-ammonium chloride. Ampholytic surfactants are compounds having both anionic and cationic groups in the same molecule. Exemplary of such compounds are derivatives of aliphatic amines containing a long chain of about 8 to 18 carbon atoms and an anionic water solubilizing group, for example carboxy sulfo, sulfo or sulfate. Examples of ampholytic detergents are: sodium sulfonate-3-dodecylaminopropane, sodium-N-methyl taurate and related substances, such as disubstituted amino acids of higher alkyl, betaines, teats, long chain olefinic amines, sulphated, and imidazoline derivatives sulfated. Ambiguous surfactants may include synthetic detergents. These ambiguous surfactants are generally derived from aliphatic quaternary ammonium compounds in which the aliphatic radical can be straight or branched chain, and where one of the aliphatic substituents contains 8 to 18 carbon atoms and another contains an anionic solubilizing group in water, for example, carboxy, sulfo or sulfate. Examples of compounds that fall within this definition are 3- (N, N-dimethyl-N-hexadecyl-ammonium) -propan-1-sulfonate and 3 (NN-dimethyl-N-hexadecylammonium) -2-hydroxy -propan-l-sulfonate.

TREATMENT Preferred medical treatment comprises a method for use in the treatment of herpes virus or other infectious diseases by resolving the physical symptoms of an infectious rash of herpes simplex virus 1 or 2 (HSV 1 or HSV 2) or other infectious microbial diseases. within 1-30 hours. This is achieved by topically applying the above-described preferred antimicrobial compound (medicine) on the infected area of the herpes simplex virus or other infectious microbial diseases, and maintaining the antimicrobial compound on the infected area for 1 to 20 hours, preferably at least 10 hours. The antimicrobial compound (medicine) can be applied in the manner previously described and more preferably covers the infected area. Conveniently, the infected area is rinsed (washed) and dried to remove any soap or residue in the infected area, before applying the antimicrobial compound (medicine). Preferably, the vesicular eruption of the herpes virus resolves in 19-24 hours and herpes lesions heal by keeping the most preferred medicine, described above, on infection, for 19-24 hours. Among the many advantages of medical treatment and medicine (compositions) of the invention, are: 1. Superior results in the termination of pain from viral herpes simplex infections and other microbial infections; 2. Outstanding performance in quickly resolving the eruptions of the herpes simplex virus and other microbial diseases. 3. Potentially saves lives of neonates and animals. 4. Reduces the risk of blindness in newborns. 5. Reduce worldwide economic losses of herpes diseases and other microbial diseases. 6. Solve the serious, emotional and mental anxieties of people suffering from herpes. 7. Materials (ingredients) readily available. 8. Economic. 9. Sure. 10. Easy to use. 11. Reliable 12. Effective. Although modalities of the invention and examples have been shown and described, it will be understood that various modifications and substitutions, as well as rearrangements of parts, components and steps of the process, methods and treatment, can be made by those skilled in the art, without departing of the novel spirit and scope of this invention.

Claims (15)

1. CLAIMS 1. A composition, which comprises: a herbaceous botanical product, of the Echinacea genus, and the benzalkonium halide.
2. 2. A composition, as claimed in claim 1, comprising, by weight: about 2 to 90% of a herbaceous botanical product of the genus Echinasea; and from about 0.005 to 0.8% of the benzalkonium halide.
3. 3. A composition, as claimed in any of the preceding claims, which includes the water that supplies a diluent and carrier.
4. 4. A composition, as claimed in any of the preceding claims, which comprises, by weight: from about 40 to 60% of a herbaceous botanical product, of the genus Echinacea; from about 0.02 to 0.30% of the benzalkonium halide; and about 20 to 60% water.
5. 5. A composition, as claimed in any of the preceding claims, wherein the benzalkonium halide consists of benzalkonium chloride.
6. 6. A composition, as claimed in any of the preceding claims, wherein the botanical product, of the Echinacea genus, comprises at least one member selected from the group consisting of. Echinacea purpurea, Echinacea augustifolia, Echinacea palidae, Echinacea vegetalis or Echinacea atribactilus.
7. 7. A composition, as claimed in any of the preceding claims, wherein the herbaceous botanical product consists of Echinacea purpurea and Echinacea augustifolia.
8. 8. A composition, as claimed in any of the preceding claims, wherein the herbaceous botanical product of the genus Echinacea comprises phytochemicals, selected from the group consisting of: equinaceous; equinacen B; Echinacein; Echinacoside; esters of caffeic acid; equinolone enzyme; glucuronide acid; inulins; inuloid; pentadecadiene; polyacelylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronarabinoxylan, Mr 35 kD); PSII (a rhamn-arabinogalastan acid, Mr, 450 kD); Sinarin; 5-di-o-caffeoylquinic acid; cyclic acid; 2,3-0-di-caffeoyl-tartaric acid; borneol; bornyl acetate; pentadeca-8 (z) -en-ona-germacrene D, caryophyllene, aryofylene-epoxide; anthocyanin, pyrrolizidine-alkaloid, lipophilic amide; iso-butylamide; polyaethylene; anthocyanin; 3-0-ß-D-glucopyroside; 3-0- (6-0-malonyl) -β-D-glucopyranoside; tusilagina; isotusilagina; dodeca-isomeric isobutylamide, tetraenoic acid; or carofilenes.
9. 9. A composition, as claimed in any of the preceding claims, wherein the herbaceous botanical product of the genus Echinacea, comprises phytochemicals that include by weight, based on the total weight of the composition: about 0.3 to 9% equinacoside; about 0.1 to 7% of PSI (4-0-methyl-glucuronoarabinoxylan, Mr of 35 kD), and PSII (rhinoarabinogalactan acid, Mr of 450 kD); about 0.1 to 10% of cyanarin (1,5-di-o-caffeoylquinic acid) and cyroic acid (2,3-0-di-caffeoyltartaric acid) and its derivatives; approximately 0.2 to 4% equinolone; approximately 0.2 to 8% equinacin B; approximately 0.1 to 6% equinacein; about 2 to 7% of anthocyanins, including cyanoid 3-0-β-D-glucopyranoside and 3-0- (6-0-malonyl) -β-D-glucopyranoside; approximately 0.01 to 0.06% pyrrolizine alkaloids, which include tusilagine and isotusilagina; approximately 0.003 to 0.008% isomeric dedeca-isobutylamides and tetraenoic acid; and approximately 0.01 to 2% of caryophylenes.
10. 10. The use of a composition, as claimed in any of the preceding claims, in the preparation of a product for the treatment of herpes simplex virus 1.
11. 11. The use of a composition, as claimed in any of the preceding claims, 1 to 9, in the preparation of a product for the treatment of herpes simplex virus 2.
12. 12. The use of a composition, as claimed in any of the preceding claims, 1 to 9, in the preparation of a product for the treatment of varicella zoster virus (herpes zoster).
13. 13. The use of a composition, as claimed in any of the preceding claims, 1 to 9, in the preparation of a product for the treatment of cytomegalovirus.
14. 14. The use of a composition, as claimed in any of the preceding claims, 1-9, in the preparation of a product for the treatment of human immunodeficiency virus (HIV).
15. 15. The use of a composition, as claimed in any of the preceding claims, 1 to 9, in the preparation of a product for the treatment of Epstein-Barr virus.